Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Adaptive Biotechnologies Corporation (ADPT)
USD21.23
+0.21 (+1.01%)
US NASDAQ Healthcare Biotechnology
Address
1165 Eastlake Avenue East 98109
Seattle, WA, US
Seattle, WA, US
CEO
Chad Robins
Website
adaptivebiotech.com
IPO
2019-06-27
CIK 1478320 ISIN US00650F1093
Description
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD21.23
+0.21 (+1.01%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
2.15
Float Shares
148.20M
Free Float %
96.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.96% | -7.13% | +5.86% | -12.87% | -6.62% | -16.63% | +42.38% | +109.60% | -58.86% | -66.40% | -66.40% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (17 ratings, all time)
Buy
Price Targets & DCF
Current price
21.23
Low
21.00
-1.1%
Consensus
21.25
+0.1%
Median
21.00
-1.1%
High
22.00
+3.6%
Ratings Trend (MoM)
88% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 5 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
21.50
+1.3%
|
| Last Year | 6 |
20.83
-1.9%
|
| All Time | 11 |
16.50
-22.3%
|
Quality scores
Altman Z-Score
1.70
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+54.8% ★ Q1'26: +35.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+63.9% ★ Q1'26: +35.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-37.0% Q1'26: -14.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-17.2% Q1'26: -25.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-17.1% Q1'26: -34.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3.1% ★ Q1'26: +4.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-9.40× Q1'26: -3.62× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 7 Rev. Ana. 6 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
85.07M
est: 82.57M (+3.0%)
|
98.38M
est: 95.07M (+3.5%)
|
154.34M
est: 152.83M (+1.0%)
|
185.31M
est: 185.10M (+0.1%)
|
170.28M
est: 168.77M (+0.9%)
|
178.96M
est: 177.62M (+0.8%)
|
276.98M
est: 265.99M (+4.1%)
|
285.33M
279.85M – 290.64M
+7.3% YoY
|
349.95M
341.52M – 359.54M
+22.6% YoY
|
426.77M
426.75M – 426.78M
+22.0% YoY
|
524.90M
514.54M – 534.46M
+23.0% YoY
|
658.00M
645.02M – 669.98M
+25.4% YoY
|
| EBITDA |
-70.60M
est: -77.04M (+8.4%)
|
-144.35M
est: -128.22M (-12.6%)
|
-193.35M
est: -216.73M (+10.8%)
|
-175.21M
est: -237.24M (+26.1%)
|
-189.27M
est: -127.34M (-48.6%)
|
-128.76M
est: -134.02M (+3.9%)
|
-29.85M
est: -200.71M (+85.1%)
|
-215.30M
-219.31M – -211.16M
-7.3% YoY
|
-264.05M
-271.29M – -257.70M
-22.6% YoY
|
-322.02M
-322.03M – -322.00M
-22.0% YoY
|
-396.06M
-403.28M – -388.25M
-23.0% YoY
|
-496.50M
-505.54M – -486.70M
-25.4% YoY
|
| EBIT |
-78.39M
est: -79.72M (+1.7%)
|
-152.82M
est: -142.02M (-7.6%)
|
-207.30M
est: -234.24M (+11.5%)
|
-196.13M
est: -259.67M (+24.5%)
|
-211.50M
est: -134.99M (-56.7%)
|
-148.02M
est: -142.07M (-4.2%)
|
-47.68M
est: -212.75M (+77.6%)
|
-228.22M
-232.47M – -223.84M
-7.3% YoY
|
-279.91M
-287.58M – -273.17M
-22.6% YoY
|
-341.35M
-341.36M – -341.33M
-22.0% YoY
|
-419.84M
-427.48M – -411.56M
-23.0% YoY
|
-526.30M
-535.88M – -515.91M
-25.4% YoY
|
| Net Income |
-68.61M
est: -148.16M (+53.7%)
|
-146.23M
est: -135.94M (-7.6%)
|
-207.28M
est: -232.25M (+10.8%)
|
-200.19M
est: -190.92M (-4.9%)
|
-225.25M
est: -222.06M (-1.4%)
|
-159.49M
est: -169.17M (+5.7%)
|
-59.50M
est: -73.94M (+19.5%)
|
-72.53M
-75.54M – -69.73M
+1.9% YoY
|
-41.30M
-44.42M – -35.23M
+43.1% YoY
|
-19.80M
-48.32M – 9.06M
+52.1% YoY
|
6.83M
6.65M – 6.99M
+134.5% YoY
|
1.52M
1.48M – 1.55M
-77.8% YoY
|
| SGA |
68.79M
est: 84.48M (-18.6%)
|
110.89M
est: 97.26M (+14.0%)
|
169.97M
est: 156.36M (+8.7%)
|
184.13M
est: 189.38M (-2.8%)
|
172.51M
est: 155.01M (+11.3%)
|
157.57M
est: 163.14M (-3.4%)
|
167.27M
est: 244.31M (-31.5%)
|
262.07M
257.04M – 266.95M
+7.3% YoY
|
321.42M
313.68M – 330.23M
+22.6% YoY
|
391.97M
391.96M – 391.99M
+22.0% YoY
|
482.11M
472.60M – 490.89M
+23.0% YoY
|
604.36M
592.43M – 615.36M
+25.4% YoY
|
| EPS |
-0.47
est: -1.01 (+53.3%)
|
-1.06
est: -1.08 (+1.8%)
|
-1.46
est: -1.49 (+2.2%)
|
-1.00
est: -1.47 (+32.0%)
|
-1.56
est: -1.47 (-6.5%)
|
-1.08
est: -1.12 (+3.1%)
|
-0.39
est: -0.49 (+20.8%)
|
-0.48
-0.50 – -0.46
+2.8% YoY
|
-0.26
-0.29 – -0.23
+45.2% YoY
|
-0.12
-0.32 – 0.06
+52.8% YoY
|
0.05
0.04 – 0.05
+136.3% YoY
|
0.01
0.01 – 0.01
-77.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
46.56M
OE per share TTM
0.29
Owner's Yield
2.17%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
71.9%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
79
Total invested
155.32M
Insider transactions (90d)
8
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Andreas Halvorsen | 29.99M | 21.90% | — | 29.99M | — | — | IN | Norway | 2021-02-16 | ↗ |
| 2 | C. Ott | 29.99M | 21.90% | — | 29.99M | — | — | IN | United States | 2021-02-16 | ↗ |
| 3 | S. Shabet | 29.99M | 21.90% | — | 29.99M | — | — | IN | United States | 2021-02-16 | ↗ |
| 4 | Viking Global Investors LP | 29.99M | 21.30% | — | 29.99M | — | 29.99M | PN | Delaware | 2022-02-14 | ↗ |
| 5 | Viking Global Performance LLC | 22.00M | 16.10% | — | 22.00M | — | — | OO | Delaware | 2021-02-16 | ↗ |
| 6 | Viking Global Equities Master Ltd. | 21.56M | 15.80% | — | 21.56M | — | — | CO | Cayman Islands | 2021-02-16 | ↗ |
| 7 | David Rosen | 14.40M | 9.76% | — | 14.40M | — | — | IN | State of Delaware | 2024-11-13 | ↗ |
| 8 | Rubric Capital Management LP | 14.40M | 9.76% | — | 14.40M | — | — | IA, PN | State of Delaware | 2024-11-13 | ↗ |
| 9 | David E. Goel | 11.57M | 8.20% | 11.57M | — | 11.57M | — | IN | United States | 2022-02-14 | ↗ |
| 10 | Matrix Capital Management Company LP | 11.57M | 8.20% | 11.57M | — | 11.57M | — | IA, PN | State of Delaware | 2022-02-14 | ↗ |
| 11 | (1) BlackRock, Inc. | 11.42M | 7.90% | 11.10M | — | 11.42M | — | HC | Delaware | 2024-01-26 | ↗ |
| 12 | The Vanguard Group - 23-1945930 | 11.03M | 7.82% | — | 60.9K | — | 149.8K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 13 | ARK Investment Management LLC | 9.20M | 6.43% | 9.20M | — | 9.20M | — | IA | Delaware, United States | 2023-02-10 | ↗ |
| 14 | Viking Long Fund GP LLC | 7.99M | 5.80% | — | 7.99M | — | — | OO | Delaware | 2021-02-16 | ↗ |
| 15 | Viking Long Fund Master Ltd. | 7.99M | 5.80% | — | 7.99M | — | — | CO | Cayman Islands | 2021-02-16 | ↗ |
| 16 | Israel A. Englander | 7.75M | 5.30% | — | 7.75M | — | 7.75M | IN | Delaware | 2024-05-28 | ↗ |
| 17 | Millennium Group Management LLC | 7.75M | 5.30% | — | 7.75M | — | 7.75M | OO | Delaware | 2024-05-28 | ↗ |
| 18 | Millennium Management LLC | 7.75M | 5.30% | — | 7.75M | — | 7.75M | OO | Delaware | 2024-05-28 | ↗ |
| 19 | Nikko Asset Management Americas, Inc. | 7.73M | 5.24% | — | 5.93M | — | 7.73M | IA | USA | 2024-11-08 | ↗ |
| 20 | Nikko Asset Management Co., Ltd. (“NAM”) | 7.73M | 5.24% | — | 7.73M | — | 7.73M | FI, IA, HC | Japan | 2024-11-05 | ↗ |
| 21 | Sumitomo Mitsui Trust Group, Inc. (“SMTG”) | 7.73M | 5.24% | — | 7.73M | — | 7.73M | FI, HC | Japan | 2024-11-05 | ↗ |
| 22 | Integrated Core Strategies (US) LLC | 7.73M | 5.20% | — | 7.73M | — | 7.73M | OO | Delaware | 2024-05-28 | ↗ |
| 23 | 52-0556948 | 4.08M | 2.90% | 932.1K | — | — | — | IA | Maryland | 2022-09-12 | ↗ |
| 24 | Viking Global Opportunities GP LLC | 1.43M | 1.20% | — | 1.43M | — | — | OO | Delaware | 2020-02-11 | ↗ |
| 25 | Viking Global Opportunities Illiquid Investments Sub-Master LP | 1.43M | 1.20% | — | 1.43M | — | — | PN | Cayman Islands | 2020-02-11 | ↗ |
| 26 | Viking Global Opportunities Portfolio GP LLC | 1.43M | 1.20% | — | 1.43M | — | — | OO | Delaware | 2020-02-11 | ↗ |
| 27 | Viking Global Equities II LP | 440.0K | 0.30% | — | 440.0K | — | — | PN | Delaware | 2021-02-16 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
79
-207 vs prev Q
New positions
12
Closed positions
215
Increased
35
Reduced
23
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 1.94M +1.9M (+100.0%) | 31.51B +31.5B (+100.0%) | 1.27% +1.267 pp | 0.05% +0.048 pp | USD16.24 +0.0% | 1 qtrs NEW |
| 2 | — | 1.65M +1.7M (+100.0%) | 26.80B +26.8B (+100.0%) | 1.09% +1.088 pp | 0.39% +0.386 pp | USD16.24 +0.0% | 1 qtrs NEW |
| 3 | VIKING GLOBAL INVESTORS LP | 29.99M +— (+0.0%) | 487.10M +38.4M (+8.6%) | 19.59% -0.135 pp | 1.29% +0.128 pp | USD40.10 -59.5% | 27 qtrs — |
| 4 | BLACKROCK, INC. | 13.33M -24.4K (-0.2%) | 216.54M +16.7M (+8.4%) | 8.71% -0.076 pp | 0.00% +0.000 pp | USD5.84 +178.1% | 6 qtrs — |
| 5 | VANGUARD GROUP INC | 11.28M +7.0K (+0.1%) | 183.22M +14.5M (+8.6%) | 7.37% -0.046 pp | 0.00% +0.000 pp | USD33.91 -52.1% | 27 qtrs — |
| 6 | PRICE T ROWE ASSOCIATES INC /MD/ | 4.39M +3.3M (+303.4%) | 71.25M +55.0M (+337.8%) | 2.87% +2.150 pp | 0.01% +0.006 pp | USD16.42 -1.1% | 27 qtrs — |
| 7 | WESTFIELD CAPITAL MANAGEMENT CO LP | 4.06M +4.1M (+100.0%) | 65.94M +65.9M (+100.0%) | 2.68% +2.676 pp | 0.27% +0.275 pp | USD16.24 +0.0% | 1 qtrs NEW |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 3.51M +110.8K (+3.3%) | 57.04M +6.2M (+12.1%) | 2.29% +0.057 pp | 0.00% +0.000 pp | USD21.07 -22.9% | 26 qtrs — |
| 9 | STATE STREET CORP | 3.18M +102.4K (+3.3%) | 51.67M +5.6M (+12.2%) | 2.08% +0.053 pp | 0.00% +0.000 pp | USD21.72 -25.2% | 26 qtrs — |
| 10 | INVESCO LTD. | 3.11M +2.2M (+248.8%) | 50.47M +37.1M (+278.6%) | 2.03% +1.444 pp | 0.01% +0.006 pp | USD15.19 +6.9% | 27 qtrs — |
| 11 | LORD, ABBETT & CO. LLC | 3.08M +1.9M (+151.2%) | 50.03M +31.7M (+172.7%) | 2.03% +1.224 pp | 0.15% +0.099 pp | USD13.04 +24.5% | 4 qtrs — |
| 12 | GOLDMAN SACHS GROUP INC | 2.90M +1.0M (+54.4%) | 47.13M +19.0M (+67.6%) | 1.90% +0.659 pp | 0.01% +0.002 pp | USD11.57 +40.4% | 27 qtrs — |
| 13 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2.76M -259.6K (-8.6%) | 44.83M -349.6K (-0.8%) | 1.80% -0.183 pp | 0.30% -0.019 pp | USD8.77 +85.2% | 6 qtrs — |
| 14 | JENNISON ASSOCIATES LLC | 2.67M +1.4M (+103.9%) | 43.44M +23.8M (+121.4%) | 1.75% +0.892 pp | 0.03% +0.015 pp | USD15.29 +6.2% | 14 qtrs — |
| 15 | AMERIPRISE FINANCIAL INC | 2.59M -3.4M (-56.6%) | 42.08M -47.3M (-52.9%) | 1.71% -2.219 pp | 0.01% -0.011 pp | USD10.78 +50.6% | 13 qtrs — |
| 16 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.42M -19.3K (-0.8%) | 39.33M +2.8M (+7.7%) | 1.58% -0.024 pp | 0.02% +0.000 pp | USD14.37 +13.0% | 4 qtrs — |
| 17 | FRED ALGER MANAGEMENT, LLC | 2.25M -268.8K (-10.7%) | 36.47M -1.1M (-3.1%) | 1.47% -0.187 pp | 0.14% -0.003 pp | USD11.86 +36.9% | 3 qtrs — |
| 18 | WELLINGTON MANAGEMENT GROUP LLP | 2.17M +1.7M (+332.1%) | 35.16M +27.7M (+369.1%) | 1.43% +1.098 pp | 0.01% +0.005 pp | USD15.94 +1.9% | 2 qtrs — |
| 19 | ARK INVESTMENT MANAGEMENT LLC | 2.14M -1.0M (-32.4%) | 34.74M -12.6M (-26.7%) | 1.41% -0.672 pp | 0.23% -0.051 pp | USD21.21 -23.4% | 23 qtrs — |
| 20 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 1.95M -1.7M (-46.6%) | 31.63M -23.0M (-42.1%) | 1.28% -1.123 pp | 0.02% -0.013 pp | USD18.61 -12.7% | 24 qtrs — |
| 21 | NIKKO ASSET MANAGEMENT AMERICAS, INC. | 1.95M -1.7M (-46.6%) | 31.62M -23.0M (-42.1%) | 1.28% -1.117 pp | 0.37% -0.164 pp | USD18.54 -12.4% | 23 qtrs — |
| 22 | D. E. SHAW & CO., INC. | 1.90M +1.2M (+157.8%) | 30.90M +19.9M (+179.8%) | 1.25% +0.769 pp | 0.02% +0.011 pp | USD14.69 +10.6% | 3 qtrs — |
| 23 | ARISTOTLE ATLANTIC PARTNERS, LLC | 1.84M -1.3M (-41.1%) | 29.92M -16.9M (-36.0%) | 1.20% -0.853 pp | 1.37% +0.012 pp | USD14.19 +14.4% | 26 qtrs — |
| 24 | BLUE WATER LIFE SCIENCE ADVISORS, LP | 1.77M -380.0K (-17.7%) | 28.67M -3.4M (-10.7%) | 1.16% -0.247 pp | 17.99% -11.288 pp | USD5.12 +217.2% | 15 qtrs — |
| 25 | DEUTSCHE BANK AG\ | 1.73M +21.3K (+1.2%) | 28.17M +2.5M (+9.9%) | 1.14% +0.017 pp | 0.01% +0.001 pp | USD14.09 +15.3% | 26 qtrs — |
| 26 | PRINCIPAL FINANCIAL GROUP INC | 1.55M +944.2K (+155.2%) | 25.21M +16.1M (+177.0%) | 1.02% +0.619 pp | 0.01% +0.008 pp | USD13.84 +17.3% | 27 qtrs — |
| 27 | DIMENSIONAL FUND ADVISORS LP | 1.38M -3.4K (-0.2%) | 22.46M +1.7M (+8.3%) | 0.91% 0.000 pp | 0.00% +0.000 pp | USD11.48 +41.5% | 24 qtrs — |
| 28 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.17M +21.0K (+1.8%) | 19.06M +1.8M (+10.5%) | 0.77% +0.016 pp | 0.00% +0.000 pp | USD23.07 -29.6% | 26 qtrs — |
| 29 | NORTHERN TRUST CORP | 1.17M -59.0K (-4.8%) | 19.05M +618.4K (+3.4%) | 0.77% -0.037 pp | 0.00% +0.000 pp | USD14.79 +9.8% | 26 qtrs — |
| 30 | MORGAN STANLEY | 1.15M +77.0K (+7.2%) | 18.66M +2.6M (+16.4%) | 0.75% +0.046 pp | 0.00% +0.000 pp | USD8.55 +89.9% | 27 qtrs — |
| 31 | ABRDN PLC | 1.05M +52.5K (+5.3%) | 17.00M +2.1M (+14.3%) | 0.69% +0.033 pp | 0.03% +0.003 pp | USD5.73 +183.4% | 9 qtrs — |
| 32 | NEXT CENTURY GROWTH INVESTORS LLC | 943.6K +412.3K (+77.6%) | 15.32M +7.4M (+92.8%) | 0.62% +0.267 pp | 1.06% +0.485 pp | USD15.52 +4.6% | 2 qtrs — |
| 33 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 922.5K -317.1K (-25.6%) | 14.98M -3.6M (-19.2%) | 0.61% -0.210 pp | 0.00% -0.001 pp | USD10.44 +55.6% | 27 qtrs — |
| 34 | QUBE RESEARCH & TECHNOLOGIES LTD | 914.2K -38.1K (-4.0%) | 14.85M +600.6K (+4.2%) | 0.60% -0.024 pp | 0.02% +0.000 pp | USD13.69 +18.6% | 3 qtrs — |
| 35 | KENNEDY CAPITAL MANAGEMENT LLC | 900.2K -373.4K (-29.3%) | 14.62M -4.4M (-23.3%) | 0.59% -0.250 pp | 0.31% -0.112 pp | USD7.53 +115.7% | 4 qtrs — |
| 36 | ALGERT GLOBAL LLC | 884.4K +362.4K (+69.4%) | 14.36M +6.6M (+83.9%) | 0.58% +0.234 pp | 0.22% +0.093 pp | USD13.94 +16.5% | 16 qtrs — |
| 37 | CATALIO CAPITAL MANAGEMENT, LP | 821.2K -63.7K (-7.2%) | 13.34M +98.3K (+0.7%) | 0.54% -0.041 pp | 2.36% -0.090 pp | USD9.80 +65.7% | 4 qtrs — |
| 38 | BANK OF AMERICA CORP /DE/ | 806.3K -791.7K (-49.5%) | 13.09M -10.8M (-45.2%) | 0.53% -0.524 pp | 0.00% -0.001 pp | USD7.88 +106.1% | 26 qtrs — |
| 39 | NUVEEN, LLC | 786.6K -389.7K (-33.1%) | 12.78M -4.8M (-27.4%) | 0.51% -0.260 pp | 0.00% -0.001 pp | USD7.43 +118.6% | 4 qtrs — |
| 40 | OBERWEIS ASSET MANAGEMENT INC/ | 744.5K +18.0K (+2.5%) | 12.09M +1.2M (+11.2%) | 0.49% +0.013 pp | 0.44% +0.026 pp | USD12.37 +31.3% | 3 qtrs — |
| 41 | ESSEX INVESTMENT MANAGEMENT CO LLC | 624.2K -14.2K (-2.2%) | 10.14M +585.9K (+6.1%) | 0.41% -0.012 pp | 1.55% +0.084 pp | USD5.67 +186.4% | 12 qtrs — |
| 42 | HILLSDALE INVESTMENT MANAGEMENT INC. | 617.0K -4.8K (-0.8%) | 10.02M +717.3K (+7.7%) | 0.41% -0.002 pp | 0.28% -0.004 pp | USD11.94 +36.0% | 3 qtrs — |
| 43 | STEMPOINT CAPITAL LP | 606.8K +606.8K (+100.0%) | 9.85M +9.9M (+100.0%) | 0.40% +0.396 pp | 1.69% +1.690 pp | USD16.24 +0.0% | 1 qtrs NEW |
| 44 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 605.0K +110.0K (+22.2%) | 9.83M +2.4M (+32.7%) | 0.40% +0.073 pp | 0.92% +0.099 pp | USD15.19 +6.9% | 2 qtrs — |
| 45 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 591.3K +535.4K (+957.0%) | 9.60M +8.8M (+1,047.4%) | 0.39% +0.353 pp | 0.03% +0.023 pp | USD16.12 +0.7% | 2 qtrs — |
| 46 | TUDOR INVESTMENT CORP ET AL | 554.0K -132.4K (-19.3%) | 9.00M -1.3M (-12.4%) | 0.37% -0.086 pp | 0.02% -0.001 pp | USD5.89 +175.7% | 8 qtrs — |
| 47 | FIRST TRUST ADVISORS LP | 539.1K -4.1K (-0.7%) | 8.75M +629.3K (+7.7%) | 0.35% -0.005 pp | 0.01% +0.000 pp | USD11.53 +40.8% | 5 qtrs — |
| 48 | CERITY PARTNERS LLC | 512.9K +80.3K (+18.6%) | 8.33M +1.9M (+28.7%) | 0.34% +0.054 pp | 0.01% +0.002 pp | USD5.98 +171.6% | 23 qtrs — |
| 49 | UBS GROUP AG | 511.9K +257.9K (+101.6%) | 8.31M +4.5M (+118.8%) | 0.33% +0.167 pp | 0.00% +0.001 pp | USD12.45 +30.4% | 26 qtrs — |
| 50 | VICTORY CAPITAL MANAGEMENT INC | 487.7K -758.9K (-60.9%) | 7.92M -10.7M (-57.5%) | 0.32% -0.501 pp | 0.00% -0.006 pp | USD7.59 +114.0% | 27 qtrs — |
| 51 | AQR CAPITAL MANAGEMENT LLC | 468.4K -140.6K (-23.1%) | 7.61M -1.5M (-16.5%) | 0.31% -0.092 pp | 0.00% -0.002 pp | USD9.45 +71.9% | 16 qtrs — |
| 52 | PEREGRINE CAPITAL MANAGEMENT LLC | 452.5K -70.3K (-13.4%) | 7.35M -472.5K (-6.0%) | 0.30% -0.047 pp | 0.23% -0.010 pp | USD11.65 +39.4% | 3 qtrs — |
| 53 | RUSSELL INVESTMENTS GROUP, LTD. | 452.2K +67.5K (+17.5%) | 7.34M +1.6M (+27.6%) | 0.30% +0.045 pp | 0.01% +0.002 pp | USD11.05 +47.0% | 12 qtrs — |
| 54 | NEUBERGER BERMAN GROUP LLC | 451.6K +348.4K (+337.9%) | 7.33M +5.8M (+375.4%) | 0.30% +0.230 pp | 0.01% +0.004 pp | USD20.43 -20.5% | 24 qtrs — |
| 55 | PRUDENTIAL FINANCIAL INC | 448.1K +138.0K (+44.5%) | 7.28M +2.6M (+56.8%) | 0.29% +0.089 pp | 0.01% +0.003 pp | USD9.36 +73.5% | 7 qtrs — |
| 56 | BALYASNY ASSET MANAGEMENT L.P. | 426.5K +426.5K (+100.0%) | 6.93M +6.9M (+100.0%) | 0.28% +0.281 pp | 0.01% +0.009 pp | USD16.24 +0.0% | 1 qtrs NEW |
| 57 | BANK OF NEW YORK MELLON CORP | 413.3K -11.3K (-2.7%) | 6.71M +360.6K (+5.7%) | 0.27% -0.007 pp | 0.00% +0.000 pp | USD31.28 -48.1% | 26 qtrs — |
| 58 | PARKMAN HEALTHCARE PARTNERS LLC | 401.7K +401.7K (+100.0%) | 6.52M +6.5M (+100.0%) | 0.26% +0.265 pp | 0.62% +0.621 pp | USD16.24 +0.0% | 1 qtrs NEW |
| 59 | CASTLEARK MANAGEMENT LLC | 390.9K +92.8K (+31.1%) | 6.35M +1.9M (+42.4%) | 0.26% +0.062 pp | 0.19% +0.061 pp | USD15.26 +6.4% | 2 qtrs — |
| 60 | FMR LLC | 386.1K +61.6K (+19.0%) | 6.27M +1.4M (+29.2%) | 0.25% +0.041 pp | 0.00% +0.000 pp | USD8.83 +83.9% | 27 qtrs — |
| 61 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 370.7K +354.2K (+2,154.4%) | 6.03M +5.8M (+2,350.4%) | 0.24% +0.231 pp | 0.07% +0.065 pp | USD16.18 +0.4% | 5 qtrs — |
| 62 | JUPITER ASSET MANAGEMENT LTD | 362.8K +91.7K (+33.8%) | 5.89M +1.8M (+45.3%) | 0.24% +0.061 pp | 0.05% +0.012 pp | USD14.83 +9.5% | 3 qtrs — |
| 63 | LEGAL & GENERAL GROUP PLC | 362.4K +116.5K (+47.4%) | 5.89M +2.2M (+60.0%) | 0.24% +0.077 pp | 0.00% +0.001 pp | USD10.97 +48.0% | 26 qtrs — |
| 64 | DIVISADERO STREET CAPITAL MANAGEMENT, LP | 361.3K +361.3K (+100.0%) | 5.87M +5.9M (+100.0%) | 0.24% +0.238 pp | 0.27% +0.275 pp | USD16.24 +0.0% | 1 qtrs NEW |
| 65 | HARVEST INVESTMENT SERVICES, LLC | 356.1K +11.6K (+3.4%) | 5.78M +629.4K (+12.2%) | 0.23% +0.008 pp | 1.09% +0.054 pp | USD12.71 +27.8% | 4 qtrs — |
| 66 | EAM INVESTORS, LLC | 351.3K -7.4K (-2.1%) | 5.71M +425.8K (+8.1%) | 0.23% -0.004 pp | 0.64% +0.030 pp | USD11.99 +35.4% | 3 qtrs — |
| 67 | RAYMOND JAMES FINANCIAL INC | 327.3K +45.7K (+16.2%) | 5.32M +1.1M (+26.2%) | 0.22% +0.031 pp | 0.00% +0.000 pp | USD11.21 +44.9% | 4 qtrs — |
| 68 | POLEN CAPITAL MANAGEMENT LLC | 325.8K +34.6K (+11.9%) | 5.29M +934.1K (+21.4%) | 0.21% +0.023 pp | 0.02% +0.008 pp | USD13.65 +19.0% | 3 qtrs — |
| 69 | ALLIANZ ASSET MANAGEMENT GMBH | 324.4K +2.6K (+0.8%) | 5.27M +454.3K (+9.4%) | 0.21% +0.002 pp | 0.01% +0.000 pp | USD13.94 +16.5% | 5 qtrs — |
| 70 | SEI INVESTMENTS CO | 316.6K +196.8K (+164.4%) | 5.14M +3.4M (+187.0%) | 0.21% +0.130 pp | 0.01% +0.003 pp | USD14.59 +11.3% | 27 qtrs — |
| 71 | AFFINITY WEALTH MANAGEMENT LLC | 314.4K +10.8K (+3.6%) | 5.11M +564.2K (+12.4%) | 0.21% +0.007 pp | 0.73% +0.061 pp | USD15.00 +8.3% | 2 qtrs — |
| 72 | BRAIDWELL LP | 312.0K -424.0K (-57.6%) | 5.07M -5.9M (-54.0%) | 0.20% -0.280 pp | 0.16% -0.165 pp | USD7.43 +118.6% | 4 qtrs — |
| 73 | BELLEVUE GROUP AG | 298.1K +129.6K (+76.9%) | 4.84M +2.3M (+92.1%) | 0.19% +0.084 pp | 0.09% +0.039 pp | USD15.52 +4.6% | 2 qtrs — |
| 74 | FRANKLIN RESOURCES INC | 282.4K +116.9K (+70.6%) | 4.59M +2.1M (+85.2%) | 0.19% +0.077 pp | 0.00% +0.001 pp | USD12.39 +31.1% | 14 qtrs — |
| 75 | BARCLAYS PLC | 279.1K +48.9K (+21.3%) | 4.53M +3.4M (+284.6%) | 0.18% +0.031 pp | 0.00% +0.001 pp | USD9.82 +65.4% | 27 qtrs — |
| 76 | JPMORGAN CHASE & CO | 265.8K +30.1K (+12.8%) | 4.32M +790.2K (+22.4%) | 0.18% +0.020 pp | 0.00% +0.000 pp | USD8.40 +93.3% | 27 qtrs — |
| 77 | BRIDGEWATER ASSOCIATES, LP | 265.5K +114.2K (+75.5%) | 4.31M +2.0M (+90.5%) | 0.17% +0.074 pp | 0.02% +0.007 pp | USD15.51 +4.7% | 2 qtrs — |
| 78 | TREXQUANT INVESTMENT LP | 264.0K -403.0K (-60.4%) | 4.29M -5.7M (-57.0%) | 0.17% -0.266 pp | 0.04% -0.065 pp | USD9.84 +65.0% | 5 qtrs — |
| 79 | LEGATO CAPITAL MANAGEMENT LLC | 238.6K +595.0 (+0.3%) | 3.87M +314.3K (+8.8%) | 0.16% +0.001 pp | 0.33% -0.054 pp | USD8.00 +103.0% | 12 qtrs — |
| 80 | PIER CAPITAL, LLC | 234.8K -400.2K (-63.0%) | 3.81M -5.7M (-59.9%) | 0.15% -0.264 pp | 0.61% -0.876 pp | USD10.24 +58.6% | 23 qtrs — |
| 81 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 229.1K +— (+0.0%) | 3.72M +293.3K (+8.6%) | 0.15% -0.001 pp | 0.06% +0.003 pp | USD11.80 +37.6% | 3 qtrs — |
| 82 | SWISS NATIONAL BANK | 225.2K +19.1K (+9.3%) | 3.66M +574.0K (+18.6%) | 0.15% +0.013 pp | 0.00% +0.000 pp | USD7.11 +128.4% | 5 qtrs — |
| 83 | MAN GROUP PLC | 211.3K +120.1K (+131.8%) | 3.43M +2.1M (+151.6%) | 0.14% +0.079 pp | 0.01% +0.004 pp | USD14.17 +14.6% | 26 qtrs — |
| 84 | JUMP FINANCIAL, LLC | 204.5K +161.6K (+376.7%) | 3.32M +2.7M (+417.5%) | 0.13% +0.107 pp | 0.04% +0.033 pp | USD15.28 +6.3% | 3 qtrs — |
| 85 | POINT72 ASSET MANAGEMENT, L.P. | 203.1K -116.4K (-36.4%) | 3.30M -1.5M (-31.0%) | 0.13% -0.076 pp | 0.00% -0.004 pp | USD11.65 +39.4% | 10 qtrs — |
| 86 | UBS ASSET MANAGEMENT AMERICAS INC | 202.7K +58.1K (+40.2%) | 3.29M +1.1M (+52.2%) | 0.13% +0.039 pp | 0.00% +0.000 pp | USD10.42 +55.9% | 5 qtrs — |
| 87 | WELLS FARGO & COMPANY/MN | 190.4K +75.6K (+65.9%) | 3.09M +1.4M (+80.1%) | 0.12% +0.049 pp | 0.00% +0.000 pp | USD13.47 +20.6% | 27 qtrs — |
| 88 | RHUMBLINE ADVISERS | 184.6K -19.3K (-9.5%) | 3.00M -52.5K (-1.7%) | 0.12% -0.014 pp | 0.00% +0.000 pp | USD18.27 -11.1% | 26 qtrs — |
| 89 | CALAMOS ADVISORS LLC | 184.0K -26.3K (-12.5%) | 2.99M -157.2K (-5.0%) | 0.12% -0.018 pp | 0.01% 0.000 pp | USD8.88 +82.9% | 4 qtrs — |
| 90 | PANAGORA ASSET MANAGEMENT INC | 164.7K +1.9K (+1.2%) | 2.68M +240.0K (+9.9%) | 0.11% +0.002 pp | 0.01% 0.000 pp | USD11.79 +37.7% | 3 qtrs — |
| 91 | ALLIANCEBERNSTEIN L.P. | 159.6K +3.3K (+2.1%) | 2.59M +253.6K (+10.8%) | 0.10% +0.002 pp | 0.00% +0.000 pp | USD14.95 +8.6% | 27 qtrs — |
| 92 | NEO IVY CAPITAL MANAGEMENT | 153.8K +153.8K (+100.0%) | 2.50M +2.5M (+100.0%) | 0.10% +0.101 pp | 0.39% +0.395 pp | USD16.24 +0.0% | 1 qtrs NEW |
| 93 | LISANTI CAPITAL GROWTH, LLC | 142.5K -156.7K (-52.4%) | 2.31M -2.2M (-48.3%) | 0.09% -0.103 pp | 0.55% -0.546 pp | USD14.96 +8.6% | 2 qtrs — |
| 94 | GOTHAM ASSET MANAGEMENT, LLC | 140.8K +13.7K (+10.8%) | 2.29M +385.0K (+20.3%) | 0.09% +0.008 pp | 0.01% +0.000 pp | USD13.07 +24.3% | 4 qtrs — |
| 95 | ENSIGN PEAK ADVISORS, INC | 140.2K -9.8K (-6.5%) | 2.28M +32.7K (+1.5%) | 0.09% -0.006 pp | 0.00% +0.000 pp | USD14.96 +8.6% | 2 qtrs — |
| 96 | KNIGHTS OF COLUMBUS ASSET ADVISORS LLC | 137.3K -54.1K (-28.3%) | 2.23M -633.2K (-22.1%) | 0.09% -0.035 pp | 0.13% -0.038 pp | USD14.96 +8.6% | 2 qtrs — |
| 97 | US BANCORP \DE\ | 131.5K +4.3K (+3.4%) | 2.14M +233.0K (+12.2%) | 0.09% +0.003 pp | 0.00% +0.000 pp | USD7.04 +130.7% | 24 qtrs — |
| 98 | TWO SIGMA ADVISERS, LP | 128.1K +128.1K (+100.0%) | 2.08M +2.1M (+100.0%) | 0.08% +0.084 pp | 0.00% +0.004 pp | USD16.24 +0.0% | 16 qtrs — |
| 99 | ADVISOR GROUP HOLDINGS, INC. | 124.3K +9.9K (+8.7%) | 2.02M +510.1K (+33.8%) | 0.08% +0.006 pp | 0.00% +0.001 pp | USD10.76 +50.9% | 24 qtrs — |
| 100 | HRT FINANCIAL LP | 124.2K +124.2K (+100.0%) | 2.02M +2.0M (+100.0%) | 0.08% +0.081 pp | 0.01% +0.006 pp | USD16.24 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.46
Bearish
Ratio by volume
0.36
Bearish
Buys
22
Sells
48
Shares acquired
291.1K
Shares disposed
811.1K
Cash buys
—
Cash sales
26.00
Net activity
-519,978
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | RUBINSTEIN JULIE | Officer | M-Exempt | A | Common Stock | 14,707 | 8.46 | 124.4K | 396,839 | D | ↗ |
| 2026-04-24 | RUBINSTEIN JULIE | Officer | M-Exempt | A | Common Stock | 14,722 | 8.46 | 124.5K | 401,192 | D | ↗ |
| 2026-04-23 | RUBINSTEIN JULIE | Officer | M-Exempt | A | Common Stock | 14,722 | 8.46 | 124.5K | 405,530 | D | ↗ |
| 2026-04-22 | RUBINSTEIN JULIE | Officer | M-Exempt | A | Common Stock | 14,722 | 8.46 | 124.5K | 409,868 | D | ↗ |
| 2026-04-21 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 30,941 | 14.66 | 453.6K | 395,146 | D | ↗ |
| 2026-04-20 | RUBINSTEIN JULIE | Officer | M-Exempt | D | Stock Option (right to buy) | 14,722 | 8.46 | 124.5K | 119,326 | D | ↗ |
| 2026-04-17 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 19,060 | 14.57 | 277.7K | 403,822 | D | ↗ |
| 2026-04-16 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 19,060 | 14.18 | 270.3K | 408,160 | D | ↗ |
| 2026-04-15 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 19,060 | 14.61 | 278.5K | 412,498 | D | ↗ |
| 2026-04-14 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 19,060 | 14.56 | 277.5K | 416,836 | D | ↗ |
| 2026-04-13 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 3,338 | 14.08 | 47.0K | 421,174 | D | ↗ |
| 2026-04-10 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 400 | 13.48 | 5.4K | 425,512 | D | ↗ |
| 2026-04-09 | RUBINSTEIN JULIE | Officer | M-Exempt | D | Stock Option (right to buy) | 14,722 | 7.27 | 107.0K | 22,831 | D | ↗ |
| 2026-04-08 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 30,841 | 14.83 | 457.4K | 434,288 | D | ↗ |
| 2026-04-08 | ROBINS HARLAN S | Officer | S-Sale | D | Common Stock | 10,000 | 14.85 | 148.5K | 1,512,058 | D | ↗ |
| 2026-04-08 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 37,263 | 15.19 | 566.0K | 2,180,518 | D | ↗ |
| 2026-04-08 | LO FRANCIS | Officer | M-Exempt | D | Stock Option (right to buy) | 2,344 | 3.99 | 9.4K | 88,297 | D | ↗ |
| 2026-04-07 | RUBINSTEIN JULIE | Officer | M-Exempt | A | Common Stock | 14,722 | 7.27 | 107.0K | 457,586 | D | ↗ |
| 2026-04-06 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 19,060 | 14.33 | 273.1K | 442,864 | D | ↗ |
| 2026-04-06 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 83,332 | 14.41 | 1.20M | 2,217,781 | D | ↗ |
| 2026-04-02 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 19,060 | 14.60 | 278.3K | 447,202 | D | ↗ |
| 2026-04-01 | RUBINSTEIN JULIE | Officer | M-Exempt | D | Stock Option (right to buy) | 14,722 | 7.27 | 107.0K | 96,441 | D | ↗ |
| 2026-03-31 | RUBINSTEIN JULIE | Officer | M-Exempt | A | Common Stock | 14,722 | 7.27 | 107.0K | 474,938 | D | ↗ |
| 2026-03-30 | RUBINSTEIN JULIE | Officer | M-Exempt | A | Common Stock | 14,722 | 7.27 | 107.0K | 479,276 | D | ↗ |
| 2026-03-27 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 2,738 | 12.49 | 34.2K | 480,876 | D | ↗ |
| 2026-03-26 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 19,060 | 14.12 | 269.1K | 468,892 | D | ↗ |
| 2026-03-25 | RUBINSTEIN JULIE | Officer | M-Exempt | D | Stock Option (right to buy) | 14,722 | 7.27 | 107.0K | 170,051 | D | ↗ |
| 2026-03-24 | RUBINSTEIN JULIE | Officer | M-Exempt | D | Stock Option (right to buy) | 14,722 | 7.27 | 107.0K | 184,773 | D | ↗ |
| 2026-03-23 | RUBINSTEIN JULIE | Officer | M-Exempt | D | Stock Option (right to buy) | 14,722 | 7.27 | 107.0K | 199,495 | D | ↗ |
| 2026-03-20 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 19,060 | 13.37 | 254.8K | 486,244 | D | ↗ |
| 2026-03-19 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 19,060 | 13.18 | 251.2K | 490,582 | D | ↗ |
| 2026-03-18 | RUBINSTEIN JULIE | Officer | M-Exempt | A | Common Stock | 14,722 | 6.55 | 96.4K | 513,980 | D | ↗ |
| 2026-03-17 | RUBINSTEIN JULIE | Officer | M-Exempt | D | Stock Option (right to buy) | 14,722 | 6.55 | 96.4K | 33,383 | D | ↗ |
| 2026-03-16 | RUBINSTEIN JULIE | Officer | M-Exempt | D | Stock Option (right to buy) | 14,722 | 6.55 | 96.4K | 48,105 | D | ↗ |
| 2026-03-13 | RUBINSTEIN JULIE | Officer | M-Exempt | A | Common Stock | 14,722 | 6.55 | 96.4K | 526,994 | D | ↗ |
| 2026-03-12 | RUBINSTEIN JULIE | Officer | M-Exempt | A | Common Stock | 14,722 | 6.55 | 96.4K | 531,332 | D | ↗ |
| 2026-03-11 | RUBINSTEIN JULIE | Officer | M-Exempt | D | Stock Option (right to buy) | 14,722 | 6.55 | 96.4K | 92,271 | D | ↗ |
| 2026-03-11 | ROBINS HARLAN S | Officer | S-Sale | D | Common Stock | 329,600 | 13.17 | 4.34M | 1,522,058 | D | ↗ |
| 2026-03-11 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 329,600 | 13.17 | 4.34M | 2,301,113 | D | ↗ |
| 2026-03-11 | PISKEL KYLE | Officer | S-Sale | D | Common Stock | 18,672 | 13.17 | 245.9K | 259,840 | D | ↗ |
| 2026-03-11 | LO FRANCIS | Officer | S-Sale | D | Common Stock | 30,593 | 14.08 | 430.7K | 291,374 | D | ↗ |
| 2026-03-11 | GRIFFIN MICHELLE RENEE | Director | S-Sale | D | Common Stock | 15,394 | 13.91 | 214.1K | 15,625 | D | ↗ |
| 2026-03-11 | BOBULSKY SUSAN | Officer | S-Sale | D | Common Stock | 41,338 | 13.17 | 544.4K | 427,775 | D | ↗ |
| 2026-03-11 | BENZENO SHARON | Officer | S-Sale | D | Common Stock | 63,103 | 13.17 | 831.1K | 272,751 | D | ↗ |
| 2026-03-10 | RUBINSTEIN JULIE | Officer | M-Exempt | D | Stock Option (right to buy) | 14,722 | 6.55 | 96.4K | 106,993 | D | ↗ |
| 2026-03-09 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 30,941 | 14.79 | 457.6K | 647,809 | D | ↗ |
| 2026-03-06 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 30,941 | 15.14 | 468.4K | 652,147 | D | ↗ |
| 2026-03-06 | ROBINS HARLAN S | Officer | A-Award | A | Common Stock | 709,220 | 0.00 | — | 1,992,324 | D | ↗ |
| 2026-03-06 | ROBINS CHAD M | Director / Officer | A-Award | A | Common Stock | 709,220 | 0.00 | — | 2,771,280 | D | ↗ |
| 2026-03-05 | RUBINSTEIN JULIE | Officer | M-Exempt | A | Common Stock | 14,722 | 6.55 | 96.4K | 594,295 | D | ↗ |
| 2026-03-05 | LO FRANCIS | Officer | S-Sale | D | Common Stock | 38,074 | 15.09 | 574.5K | 321,967 | D | ↗ |
| 2026-03-04 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 30,941 | 16.60 | 513.6K | 579,573 | D | ↗ |
| 2026-03-04 | ROBINS HARLAN S | Officer | A-Award | A | Common Stock | 127,813 | 0.00 | — | 1,283,104 | D | ↗ |
| 2026-03-04 | ROBINS CHAD M | Director / Officer | A-Award | A | Common Stock | 127,813 | 0.00 | — | 2,062,060 | D | ↗ |
| 2026-03-04 | PISKEL KYLE | Officer | A-Award | A | Common Stock | 61,875 | 0.00 | — | 278,512 | D | ↗ |
| 2026-03-04 | OWEN KATEY EINTERZ | Director | A-Award | A | Common Stock | 15,625 | 0.00 | — | 88,254 | D | ↗ |
| 2026-03-04 | NEUPERT PETER M | Director | A-Award | A | Common Stock | 15,625 | 0.00 | — | 240,315 | D | ↗ |
| 2026-03-04 | LO FRANCIS | Officer | A-Award | A | Common Stock | 44,063 | 0.00 | — | 360,041 | D | ↗ |
| 2026-03-04 | HERSHBERG ROBERT | Director | A-Award | A | Common Stock | 15,625 | 0.00 | — | 62,347 | D | ↗ |
| 2026-03-04 | GRIFFIN MICHELLE RENEE | Director | A-Award | A | Common Stock | 15,625 | 0.00 | — | 31,019 | D | ↗ |
| 2026-03-04 | BOBULSKY SUSAN | Officer | A-Award | A | Common Stock | 59,375 | 0.00 | — | 406,613 | D | ↗ |
| 2026-03-04 | BENZENO SHARON | Officer | A-Award | A | Common Stock | 39,063 | 0.00 | — | 335,854 | D | ↗ |
| 2026-03-03 | RUBINSTEIN JULIE | Officer | M-Exempt | A | Common Stock | 14,722 | 6.55 | 96.4K | 602,971 | D | ↗ |
| 2026-03-03 | ROBINS HARLAN S | Officer | S-Sale | D | Common Stock | 14,233 | 16.52 | 235.1K | 1,155,291 | D | ↗ |
| 2026-03-03 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 50,703 | 15.49 | 785.4K | 1,936,627 | D | ↗ |
| 2026-03-03 | GRIFFIN MICHELLE RENEE | Director | M-Exempt | D | Stock Option (right to buy) | 48,044 | 3.99 | 191.7K | 0 | D | ↗ |
| 2026-03-02 | ROBINS HARLAN S | Officer | S-Sale | D | Common Stock | 10,000 | 15.72 | 157.2K | 1,169,524 | D | ↗ |
| 2026-03-02 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 289,024 | 15.82 | 4.57M | 1,987,330 | D | ↗ |
| 2026-02-27 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 182,891 | 15.99 | 2.92M | 2,276,354 | D | ↗ |
| 2026-02-04 | PISKEL KYLE | Officer | M-Exempt | D | Stock Option (right to buy) | 2,145 | 12.14 | 26.0K | 2,146 | D | ↗ |
| 2026-02-03 | ROBINS HARLAN S | Officer | S-Sale | D | Common Stock | 8,120 | 19.00 | 154.3K | 1,179,524 | D | ↗ |
| 2026-02-02 | ROBINS HARLAN S | Officer | S-Sale | D | Common Stock | 34,668 | 18.60 | 644.8K | 1,187,644 | D | ↗ |
| 2026-02-02 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 124,998 | 18.44 | 2.30M | 2,459,245 | D | ↗ |
| 2026-01-12 | PISKEL KYLE | Officer | M-Exempt | D | Stock Option (right to buy) | 4,290 | 12.14 | 52.1K | 4,291 | D | ↗ |
| 2026-01-12 | LO FRANCIS | Officer | M-Exempt | A | Common Stock | 14,215 | 3.99 | 56.7K | 395,568 | D | ↗ |
| 2026-01-06 | ROBINS HARLAN S | Officer | S-Sale | D | Common Stock | 10,000 | 16.44 | 164.4K | 1,222,312 | D | ↗ |
| 2026-01-05 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 124,998 | 15.59 | 1.95M | 2,584,243 | D | ↗ |
| 2026-01-02 | LO FRANCIS | Officer | M-Exempt | A | Common Stock | 3,125 | 3.99 | 12.5K | 319,103 | D | ↗ |
| 2025-12-22 | LO FRANCIS | Officer | M-Exempt | A | Common Stock | 2,194 | 8.46 | 18.6K | 319,272 | D | ↗ |
| 2025-12-15 | LO FRANCIS | Officer | M-Exempt | D | Stock Option (right to buy) | 39,849 | 3.99 | 159.0K | 110,175 | D | ↗ |
| 2025-12-10 | HERSHBERG ROBERT | Director | S-Sale | D | Common Stock | 22,968 | 16.00 | 367.5K | 46,722 | D | ↗ |
| 2025-12-04 | ROBINS HARLAN S | Officer | S-Sale | D | Common Stock | 10,000 | 16.61 | 166.1K | 1,232,312 | D | ↗ |
| 2025-12-04 | BENZENO SHARON | Officer | M-Exempt | A | Common Stock | 4,157 | 3.99 | 16.6K | 309,395 | D | ↗ |
| 2025-12-03 | ROBINS HARLAN S | Officer | S-Sale | D | Common Stock | 27,212 | 18.61 | 506.4K | 1,242,312 | D | ↗ |
| 2025-12-01 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 124,998 | 18.94 | 2.37M | 2,709,241 | D | ↗ |
| 2025-11-28 | PISKEL KYLE | Officer | M-Exempt | D | Stock Option (right to buy) | 94,384 | 12.14 | 1.15M | 8,581 | D | ↗ |
| 2025-11-26 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 35,736 | 19.68 | 703.3K | 2,834,239 | D | ↗ |
| 2025-11-21 | BENZENO SHARON | Officer | M-Exempt | A | Common Stock | 834 | 6.27 | 5.2K | 297,625 | D | ↗ |
| 2025-11-20 | BENZENO SHARON | Officer | M-Exempt | D | Stock Option (right to buy) | 68,961 | 12.14 | 837.2K | 136,970 | D | ↗ |
| 2025-11-17 | PISKEL KYLE | Officer | S-Sale | D | Common Stock | 238 | 14.05 | 3.3K | 269,343 | D | ↗ |
| 2025-11-12 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 1,867 | 15.00 | 28.0K | 2,869,975 | D | ↗ |
| 2025-11-11 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 1,237 | 14.57 | 18.0K | 2,871,851 | D | ↗ |
| 2025-11-10 | ROBINS HARLAN S | Officer | S-Sale | D | Common Stock | 10,000 | 14.82 | 148.2K | 1,269,524 | D | ↗ |
| 2025-11-10 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 86,161 | 14.73 | 1.27M | 2,873,088 | D | ↗ |
| 2025-05-16 | PISKEL KYLE | Officer | S-Sale | D | Common Stock | 1,929 | 8.89 | 17.1K | 269,581 | D | ↗ |
| 2025-05-15 | PISKEL KYLE | Officer | A-Award | A | Common Stock | 7,815 | 0.00 | — | 279,325 | D | ↗ |
| 2025-05-01 | ROBINS HARLAN S | Officer | S-Sale | D | Common Stock | 68,412 | 7.35 | 502.8K | 1,279,524 | D | ↗ |
| 2025-03-24 | ROBINS HARLAN S | Officer | M-Exempt | A | Common Stock | 1,698 | 6.32 | 10.7K | 1,281,222 | D | ↗ |
| 2025-03-14 | PISKEL KYLE | Officer | M-Exempt | A | Common Stock | 2,500 | 6.32 | 15.8K | 271,510 | D | ↗ |
| 2025-03-13 | GRIFFIN MICHELLE RENEE | Director | S-Sale | D | Common Stock | 36,291 | 7.19 | 260.9K | 15,394 | D | ↗ |
| 2025-03-12 | HERSHBERG ROBERT | Director | S-Sale | D | Common Stock | 53,000 | 7.59 | 402.3K | 69,690 | D | ↗ |
| 2025-03-10 | NEUPERT PETER M | Director | S-Sale | D | Common Stock | 10,000 | 7.05 | 70.5K | 224,690 | D | ↗ |
| 2025-03-06 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 102,218 | 7.64 | 780.9K | 2,959,249 | D | ↗ |
| 2025-03-06 | GRIFFIN MICHELLE RENEE | Director | S-Sale | D | Common Stock | 15,664 | 7.94 | 124.4K | 51,685 | D | ↗ |
| 2025-03-05 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 19,461 | 6.99 | 136.0K | 588,249 | D | ↗ |
| 2025-03-05 | ROBINS HARLAN S | Officer | S-Sale | D | Common Stock | 56,053 | 6.99 | 391.8K | 1,279,524 | D | ↗ |
| 2025-03-05 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 36,145 | 6.99 | 252.7K | 2,814,350 | D | ↗ |
| 2025-03-05 | PISKEL KYLE | Officer | S-Sale | D | Common Stock | 3,103 | 6.97 | 21.6K | 276,227 | D | ↗ |
| 2025-03-05 | LO FRANCIS | Officer | S-Sale | D | Common Stock | 13,790 | 6.99 | 96.4K | 332,846 | D | ↗ |
| 2025-03-05 | BOBULSKY SUSAN | Officer | S-Sale | D | Common Stock | 26,023 | 6.98 | 181.6K | 347,238 | D | ↗ |
| 2025-03-05 | BENZENO SHARON | Officer | S-Sale | D | Common Stock | 3,065 | 6.99 | 21.4K | 392,723 | D | ↗ |
| 2025-03-04 | RUBINSTEIN JULIE | Officer | A-Award | A | Common Stock | 175,000 | 0.00 | — | 647,754 | D | ↗ |
| 2025-03-04 | ROBINS HARLAN S | Officer | A-Award | A | Common Stock | 355,000 | 0.00 | — | 1,376,180 | D | ↗ |
| 2025-03-04 | ROBINS CHAD M | Director / Officer | A-Award | A | Common Stock | 355,000 | 0.00 | — | 2,931,701 | D | ↗ |
| 2025-03-04 | Pellini Michael J | Director | A-Award | A | Stock Option (right to buy) | 23,726 | 8.12 | 192.7K | 23,726 | D | ↗ |
| 2025-03-04 | PISKEL KYLE | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 279,330 | D | ↗ |
| 2025-03-04 | OWEN KATEY EINTERZ | Director | A-Award | A | Stock Option (right to buy) | 23,726 | 8.12 | 192.7K | 23,726 | D | ↗ |
| 2025-03-04 | NEUPERT PETER M | Director | A-Award | A | Stock Option (right to buy) | 23,726 | 8.12 | 192.7K | 23,726 | D | ↗ |
| 2025-03-04 | LO FRANCIS | Officer | A-Award | A | Common Stock | 99,976 | 0.00 | — | 353,721 | D | ↗ |
| 2025-03-04 | HERSHBERG ROBERT | Director | A-Award | A | Stock Option (right to buy) | 23,726 | 8.12 | 192.7K | 23,726 | D | ↗ |
| 2025-03-04 | GRIFFIN MICHELLE RENEE | Director | A-Award | A | Stock Option (right to buy) | 23,726 | 8.12 | 192.7K | 23,726 | D | ↗ |
| 2025-03-04 | BOBULSKY SUSAN | Officer | A-Award | A | Common Stock | 119,971 | 0.00 | — | 373,261 | D | ↗ |
| 2025-03-04 | BENZENO SHARON | Officer | A-Award | A | Common Stock | 109,973 | 0.00 | — | 437,388 | D | ↗ |
| 2025-02-20 | ROBINS CHAD M | Director / Officer | M-Exempt | A | Common Stock | 99,107 | 6.32 | 626.4K | 2,675,808 | D | ↗ |
| 2025-02-19 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 186,080 | 8.46 | 1.57M | 2,576,701 | D | ↗ |
| 2025-02-18 | ROBINS CHAD M | Director / Officer | M-Exempt | A | Common Stock | 211,160 | 6.32 | 1.33M | 2,787,861 | D | ↗ |
| 2025-02-14 | ROBINS CHAD M | Director / Officer | M-Exempt | A | Common Stock | 158,921 | 6.32 | 1.00M | 2,735,622 | D | ↗ |
| 2025-02-13 | ROBINS CHAD M | Director / Officer | M-Exempt | A | Common Stock | 100,287 | 6.32 | 633.8K | 2,676,988 | D | ↗ |
| 2024-11-18 | PISKEL KYLE | Officer | S-Sale | D | Common Stock | 248 | 4.98 | 1.2K | 154,330 | D | ↗ |
| 2024-10-08 | BOBULSKY SUSAN | Officer | M-Exempt | A | Common Stock | 5,000 | 1.98 | 9.9K | 253,290 | D | ↗ |
| 2024-08-22 | Taylor Stacy L | Officer | S-Sale | D | Common Stock | 26,922 | 4.50 | 121.1K | 139,365 | — | ↗ |
| 2024-05-15 | PISKEL KYLE | Officer | A-Award | A | Common Stock | 31,260 | 0.00 | — | 154,578 | — | ↗ |
| 2024-03-12 | NEUPERT PETER M | Director | M-Exempt | A | Common Stock | 15,000 | 0.84 | 12.6K | 169,296 | — | ↗ |
| 2024-03-05 | Taylor Stacy L | Officer | S-Sale | D | Common Stock | 6,772 | 3.43 | 23.2K | 172,896 | — | ↗ |
| 2024-03-05 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 13,490 | 3.56 | 48.0K | 472,754 | — | ↗ |
| 2024-03-05 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 42,794 | 3.43 | 146.8K | 2,576,701 | — | ↗ |
| 2024-03-05 | PISKEL KYLE | Officer | S-Sale | D | Common Stock | 7,727 | 3.43 | 26.5K | 123,318 | — | ↗ |
| 2024-03-05 | PETERSON TYCHO | Officer | S-Sale | D | Common Stock | 15,456 | 3.44 | 53.2K | 531,553 | — | ↗ |
| 2024-03-05 | LO FRANCIS | Officer | S-Sale | D | Common Stock | 1,813 | 3.44 | 6.2K | 253,745 | — | ↗ |
| 2024-03-05 | BOBULSKY SUSAN | Officer | S-Sale | D | Common Stock | 6,975 | 3.44 | 24.0K | 248,290 | — | ↗ |
| 2024-03-05 | BENZENO SHARON | Officer | S-Sale | D | Common Stock | 18,644 | 3.44 | 64.1K | 327,415 | — | ↗ |
| 2024-03-04 | Taylor Stacy L | Officer | A-Award | A | Common Stock | 39,990 | 0.00 | — | 179,668 | — | ↗ |
| 2024-03-04 | RUBINSTEIN JULIE | Officer | A-Award | A | Common Stock | 175,000 | 0.00 | — | 511,824 | — | ↗ |
| 2024-03-04 | ROBINS HARLAN S | Officer | A-Award | A | Common Stock | 354,610 | 0.00 | — | 1,021,180 | — | ↗ |
| 2024-03-04 | ROBINS CHAD M | Director / Officer | A-Award | A | Common Stock | 354,610 | 0.00 | — | 2,625,374 | — | ↗ |
| 2024-03-04 | Pellini Michael J | Director | A-Award | A | Common Stock | 31,328 | 0.00 | — | 54,296 | — | ↗ |
| 2024-03-04 | PISKEL KYLE | Officer | A-Award | A | Common Stock | 43,740 | 0.00 | — | 131,045 | — | ↗ |
| 2024-03-04 | PETERSON TYCHO | Officer | A-Award | A | Common Stock | 147,790 | 0.00 | — | 547,009 | — | ↗ |
| 2024-03-04 | OWEN KATEY EINTERZ | Director | A-Award | A | Common Stock | 31,328 | 0.00 | — | 57,235 | — | ↗ |
| 2024-03-04 | NEUPERT PETER M | Director | A-Award | A | Stock Option (right to buy) | 48,044 | 3.99 | 191.7K | 48,044 | — | ↗ |
| 2024-03-04 | LO FRANCIS | Officer | A-Award | A | Common Stock | 99,976 | 0.00 | — | 268,445 | — | ↗ |
| 2024-03-04 | HERSHBERG ROBERT | Director | A-Award | A | Stock Option (right to buy) | 48,044 | 3.99 | 191.7K | 48,044 | — | ↗ |
| 2024-03-04 | GRIFFIN MICHELLE RENEE | Director | A-Award | A | Common Stock | 31,328 | 0.00 | — | 51,955 | — | ↗ |
| 2024-03-04 | BOBULSKY SUSAN | Officer | A-Award | A | Stock Option (right to buy) | 199,549 | 3.99 | 796.2K | 199,549 | — | ↗ |
| 2024-03-04 | BENZENO SHARON | Officer | A-Award | A | Stock Option (right to buy) | 199,549 | 3.99 | 796.2K | 199,549 | — | ↗ |
| 2024-01-25 | BOBULSKY SUSAN | Officer | — | D | Common Stock | 0 | 0.00 | — | 128,302 | — | ↗ |
| 2023-12-13 | NEUPERT PETER M | Director | M-Exempt | A | Common Stock | 100,000 | 0.84 | 84.0K | 122,968 | — | ↗ |
| 2023-11-16 | PISKEL KYLE | Officer | S-Sale | D | Common Stock | 259 | 4.13 | 1.1K | 87,305 | — | ↗ |
| 2023-08-08 | SOOD NITIN | Officer | S-Sale | D | Common Stock | 10,550 | 6.54 | 69.0K | 214,808 | — | ↗ |
| 2023-08-07 | SOOD NITIN | Officer | S-Sale | D | Common Stock | 5,652 | 6.78 | 38.3K | 225,358 | — | ↗ |
| 2023-06-20 | PETERSON TYCHO | Officer | M-Exempt | A | Common Stock | 134,961 | 7.30 | 985.2K | 534,180 | — | ↗ |
| 2023-06-15 | PETERSON TYCHO | Officer | M-Exempt | A | Common Stock | 14,328 | 7.30 | 104.6K | 413,547 | — | ↗ |
| 2023-06-02 | PETERSON TYCHO | Officer | S-Sale | D | Common Stock | 38,000 | 7.16 | 272.1K | 454,891 | — | ↗ |
| 2023-04-11 | ADAMS R MARK | Officer | S-Sale | D | Common Stock | 2,308 | 8.63 | 19.9K | 175,361 | — | ↗ |
| 2023-04-10 | ADAMS R MARK | Officer | S-Sale | D | Common Stock | 817 | 8.50 | 6.9K | 177,669 | — | ↗ |
| 2023-03-27 | GRIFFIN MICHELLE RENEE | Director | S-Sale | D | Common Stock | 2,341 | 8.49 | 19.9K | 20,627 | — | ↗ |
| 2023-03-07 | Taylor Stacy L | Officer | S-Sale | D | Common Stock | 13,387 | 8.60 | 115.1K | 139,678 | — | ↗ |
| 2023-03-07 | SOOD NITIN | Officer | S-Sale | D | Common Stock | 9,813 | 8.60 | 84.4K | 231,010 | — | ↗ |
| 2023-03-07 | ADAMS R MARK | Officer | S-Sale | D | Common Stock | 17,155 | 8.60 | 147.5K | 178,486 | — | ↗ |
| 2023-03-06 | Trigg Leslie | Director | A-Award | A | Stock Option (right to buy) | 23,329 | 8.46 | 197.4K | 23,329 | — | ↗ |
| 2023-03-06 | Taylor Stacy L | Officer | A-Award | A | Common Stock | 85,697 | 0.00 | — | 158,556 | — | ↗ |
| 2023-03-06 | SOOD NITIN | Officer | A-Award | A | Common Stock | 132,979 | 0.00 | — | 247,484 | — | ↗ |
| 2023-03-06 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 22,668 | 8.57 | 194.3K | 336,824 | — | ↗ |
| 2023-03-06 | ROBINS HARLAN S | Officer | A-Award | A | Common Stock | 354,610 | 0.00 | — | 666,570 | — | ↗ |
| 2023-03-06 | ROBINS CHAD M | Director / Officer | A-Award | A | Common Stock | 354,610 | 0.00 | — | 2,270,764 | — | ↗ |
| 2023-03-06 | Pellini Michael J | Director | A-Award | A | Stock Option (right to buy) | 23,329 | 8.46 | 197.4K | 23,329 | — | ↗ |
| 2023-03-06 | PISKEL KYLE | Officer | S-Sale | D | Common Stock | 3,300 | 8.57 | 28.3K | 87,793 | — | ↗ |
| 2023-03-06 | PETERSON TYCHO | Officer | A-Award | A | Common Stock | 118,203 | 0.00 | — | 492,891 | — | ↗ |
| 2023-03-06 | OWEN KATEY EINTERZ | Director | A-Award | A | Common Stock | 14,775 | 0.00 | — | 25,907 | — | ↗ |
| 2023-03-06 | NEUPERT PETER M | Director | A-Award | A | Common Stock | 14,775 | 0.00 | — | 22,968 | — | ↗ |
| 2023-03-06 | LO FRANCIS | Officer | A-Award | A | Stock Option (right to buy) | 128,599 | 8.46 | 1.09M | 128,599 | — | ↗ |
| 2023-03-06 | HERSHBERG ROBERT | Director | A-Award | A | Common Stock | 14,775 | 0.00 | — | 75,968 | — | ↗ |
| 2023-03-06 | GRIFFIN MICHELLE RENEE | Director | A-Award | A | Common Stock | 14,775 | 0.00 | — | 22,968 | — | ↗ |
| 2023-03-06 | Conroy Kevin T | Director | A-Award | A | Stock Option (right to buy) | 23,329 | 8.46 | 197.4K | 23,329 | — | ↗ |
| 2023-03-06 | BENZENO SHARON | Officer | A-Award | A | Common Stock | 132,979 | 0.00 | — | 235,575 | — | ↗ |
| 2023-03-06 | ADAMS R MARK | Officer | A-Award | A | Stock Option (right to buy) | 133,033 | 8.46 | 1.13M | 133,033 | — | ↗ |
| 2023-02-02 | HERSHBERG ROBERT | Director | M-Exempt | D | Stock Option (Right to Buy) | 53,000 | 0.45 | 23.9K | 0 | — | ↗ |
| 2023-01-10 | ADAMS R MARK | Officer | S-Sale | D | Common Stock | 2,130 | 8.58 | 18.3K | 113,518 | — | ↗ |
| 2023-01-09 | ADAMS R MARK | Officer | S-Sale | D | Common Stock | 995 | 8.50 | 8.5K | 115,648 | — | ↗ |
| 2022-11-16 | PISKEL KYLE | Officer | S-Sale | D | Common Stock | 307 | 8.87 | 2.7K | 47,358 | — | ↗ |
| 2022-11-01 | SOOD NITIN | Officer | S-Sale | D | Common Stock | 31,066 | 8.00 | 248.5K | 114,505 | — | ↗ |
| 2022-10-10 | ADAMS R MARK | Officer | S-Sale | D | Common Stock | 2,284 | 7.13 | 16.3K | 116,643 | — | ↗ |
| 2022-10-07 | ADAMS R MARK | Officer | S-Sale | D | Common Stock | 841 | 7.61 | 6.4K | 118,927 | — | ↗ |
| 2022-03-09 | ROBINS CHAD M | Director / Officer | M-Exempt | D | Common Stock | 14,815 | 6.32 | 93.6K | 1,930,969 | — | ↗ |
| 2022-03-08 | Taylor Stacy L | Officer | S-Sale | D | Common Stock | 2,387 | 11.44 | 27.3K | 72,859 | — | ↗ |
| 2022-03-08 | ROBINS CHAD M | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 14,815 | 6.32 | 93.6K | 770,370 | — | ↗ |
| 2022-03-08 | LO FRANCIS | Officer | S-Sale | D | Common Stock | 3,582 | 11.44 | 41.0K | 89,588 | — | ↗ |
| 2022-03-07 | Taylor Stacy L | Officer | S-Sale | D | Common Stock | 1,569 | 12.01 | 18.8K | 75,246 | — | ↗ |
| 2022-03-07 | RUBINSTEIN JULIE | Officer | S-Sale | D | Common Stock | 4,613 | 12.01 | 55.4K | 226,513 | — | ↗ |
| 2022-03-07 | ROBINS CHAD M | Director / Officer | S-Sale | D | Common Stock | 4,424 | 12.01 | 53.1K | 1,916,154 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-77.0K
Shares Outstanding
153.98M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Chad Robins Chief Executive Officer and Chairman | 698.3K | — | 7.68M | — | 703.4K | 5.0K | 9.08M | 84.51% | ↗ |
| 2 | 2025 | Harlan Robins, PhD Chief Scientific Officer | 558.7K | — | 7.68M | — | 270.8K | 5.0K | 8.51M | 90.19% | ↗ |
| 3 | 2025 | Julie Rubinstein President and Chief Operating Officer | 542.4K | — | 3.78M | — | 273.2K | 4.9K | 4.60M | 82.18% | ↗ |
| 4 | 2025 | Susan Bobulsky Chief Commercial Officer, MRD | 435.8K | — | 1.88M | 997.3K | 226.0K | 4.5K | 3.55M | 81.22% | ↗ |
| 5 | 2025 | Kyle Piskel Chief Financial Officer | 400.0K | — | 2.70M | — | 203.3K | 5.0K | 3.31M | 81.63% | ↗ |
| 6 | 2024 | Chad Robins Chief Executive Officer and Chairman | 677.9K | — | 3.72M | — | 573.6K | 5.4K | 4.97M | 74.73% | ↗ |
| 7 | 2024 | Harlan Robins, PhD Chief Scientific Officer | 542.4K | — | 3.72M | — | 276.6K | 5.0K | 4.54M | 81.85% | ↗ |
| 8 | 2024 | Julie Rubinstein President and Chief Operating Officer | 530.5K | — | 1.83M | — | 275.2K | 4.9K | 2.64M | 69.35% | ↗ |
| 9 | 2024 | Sharon Benzeno, PhD Chief Commercial Officer, IM | 475.0K | — | 530.6K | 545.6K | 240.5K | 4.9K | 1.80M | 59.90% | ↗ |
| 10 | 2024 | Susan Bobulsky Chief Commercial Officer, MRD | 414.6K | — | 530.6K | 545.6K | 211.9K | 4.0K | 1.71M | 63.06% | ↗ |
| 11 | 2024 | Tycho Peterson Former Chief Financial Officer | 114.4K | — | 1.55M | — | — | 3.8K | 1.67M | 92.91% | ↗ |
| 12 | 2024 | Kyle Piskel Chief Financial Officer | 361.2K | — | 783.2K | — | 141.2K | 4.8K | 1.29M | 60.70% | ↗ |
| 13 | 2023 | Chad Robins Chief Executive Officer and Chairman | 663.0K | — | 7.90M | — | 318.2K | 22.3K | 8.90M | 88.73% | ↗ |
| 14 | 2023 | Harlan Robins, PhD Chief Scientific Officer | 530.5K | — | 7.90M | — | 175.7K | 4.9K | 8.61M | 91.74% | ↗ |
| 15 | 2023 | Julie Rubinstein President and Chief Operating Officer | 530.5K | — | 1.13M | 1.12M | 185.7K | 4.9K | 2.97M | 75.73% | ↗ |
| 16 | 2023 | Sharon Benzeno, PhD Chief Commercial Officer, IM | 475.0K | — | 1.13M | 1.12M | 151.4K | 4.3K | 2.88M | 78.11% | ↗ |
| 17 | 2023 | Tycho Peterson Former Chief Financial Officer | 425.0K | — | 1,000.0K | 1,000.0K | 135.5K | 4.9K | 2.57M | 77.96% | ↗ |
| 18 | 2023 | Susan Bobulsky Chief Commercial Officer, MRD | 355.0K | — | 500.0K | 500.0K | 95.9K | 4.3K | 1.46M | 68.72% | ↗ |
| 19 | 2023 | Kyle Piskel Chief Financial Officer | 305.3K | — | 370.0K | — | 64.8K | 4.0K | 744.0K | 49.73% | ↗ |
| 20 | 2022 | Chad Robins Chief Executive Officer and Chairman | 658.2K | — | 7.67M | — | 450.8K | 76.3K | 8.85M | 86.61% | ↗ |
| 21 | 2022 | Harlan Robins, PhD Chief Scientific Officer | 526.6K | — | 3.00M | 4.70M | 228.8K | 4.3K | 8.46M | 91.02% | ↗ |
| 22 | 2022 | Julie Rubinstein President and Chief Operating Officer | 526.6K | — | 2.25M | 3.52M | 228.8K | 5.1K | 6.54M | 88.36% | ↗ |
| 23 | 2022 | Tycho Peterson Chief Financial Officer | 247.9K | — | 2.74M | 2.84M | 110.6K | 4.2K | 5.94M | 93.89% | ↗ |
| 24 | 2022 | Tycho Peterson Former Chief Financial Officer | 247.9K | — | 2.74M | 2.84M | 110.6K | 4.2K | 5.94M | 93.89% | ↗ |
| 25 | 2022 | Sharon Benzeno Chief Commercial Officer, Immune Medicine | 456.3K | — | 1,000.0K | 1.57M | 210.8K | 4.3K | 3.24M | 79.27% | ↗ |
| 26 | 2022 | Sharon Benzeno, PhD Chief Commercial Officer, IM | 456.3K | — | 1,000.0K | 1.57M | 210.8K | 4.3K | 3.24M | 79.27% | ↗ |
| 27 | 2022 | Kyle Piskel Interim Chief Financial Officer | 293.6K | — | 500.0K | 783.2K | 78.2K | 4.2K | 1.66M | 77.34% | ↗ |
| 28 | 2022 | Kyle Piskel Chief Financial Officer | 293.6K | — | 500.0K | 783.2K | 78.2K | 4.2K | 1.66M | 77.34% | ↗ |
| 29 | 2022 | Chad Cohen Former Chief Financial Officer | 54.1K | — | — | — | — | 18.2K | 72.2K | 0.00% | ↗ |
| 30 | 2021 | Chad Robins Chief Executive Officer and Chairman | 639.1K | — | 3.00M | 4.59M | 463.5K | 56.3K | 8.75M | 86.76% | ↗ |
| 31 | 2021 | Harlan Robins, PhD Chief Scientific Officer | 511.3K | — | 3.00M | 4.59M | 238.2K | 4.3K | 8.35M | 90.97% | ↗ |
| 32 | 2021 | Nitin Sood Chief Commercial Officer, MRD | 187.8K | — | 3.00M | 3.11M | 87.4K | 630.00 | 6.39M | 95.68% | ↗ |
| 33 | 2021 | Julie Rubinstein President and Chief Operating Officer | 511.3K | — | 2.00M | 3.06M | 238.2K | 4.6K | 5.82M | 87.03% | ↗ |
| 34 | 2021 | Julie Rubinstein President | 511.3K | — | 2.00M | 3.06M | 238.2K | 4.6K | 5.82M | 87.03% | ↗ |
| 35 | 2021 | Chad Cohen Chief Financial Officer | 429.4K | — | 900.0K | 1.38M | 200.0K | 4.6K | 2.91M | 78.23% | ↗ |
| 36 | 2021 | Chad Cohen Former Chief Financial Officer | 429.4K | — | 900.0K | 1.38M | 200.0K | 4.6K | 2.91M | 78.23% | ↗ |
| 37 | 2020 | Chad Robins Chief Executive Officer and Chairman | 597.4K | — | — | 6.01M | 500.0K | 20.1K | 7.13M | 84.33% | ↗ |
| 38 | 2020 | Harlan Robins, PhD Chief Scientific Officer | 493.8K | — | — | 6.01M | 250.0K | 3.9K | 6.76M | 88.94% | ↗ |
| 39 | 2020 | Julie Rubinstein President | 481.1K | — | — | 4.01M | 250.0K | 3.7K | 4.74M | 84.51% | ↗ |
| 40 | 2020 | Julie Rubinstein President and Chief Operating Officer | 481.1K | — | — | 4.01M | 250.0K | 3.7K | 4.74M | 84.51% | ↗ |
| 41 | 2020 | Mark Adams, PhD Chief Operating Officer | — | — | 1.41M | — | 112.0K | 10.5K | 2.70M | 52.04% | ↗ |
| 42 | 2020 | Chad Cohen Former Chief Financial Officer | 412.0K | — | — | 1.70M | 210.0K | 3.9K | 2.33M | 73.13% | ↗ |
| 43 | 2020 | Chad Cohen Chief Financial Officer | 412.0K | — | — | 1.70M | 210.0K | 3.9K | 2.33M | 73.13% | ↗ |
| 44 | 2019 | Lance Baldo, MD Chief Medical Officer | 311.5K | 237.5K | — | 3.16M | — | — | 3.71M | 85.19% | ↗ |
| 45 | 2019 | Chad Robins Chairman and Chief Executive Officer | 492.6K | — | — | 1.98M | 386.0K | — | 2.86M | 69.24% | ↗ |
| 46 | 2019 | Chad Robins Chief Executive Officer and Chairman | 492.6K | — | — | 1.98M | 386.0K | — | 2.86M | 69.24% | ↗ |
| 47 | 2019 | Harlan Robins, PhD Chief Scientific Officer | 431.8K | — | — | 1.98M | 237.5K | — | 2.65M | 74.71% | ↗ |
| 48 | 2019 | Julie Rubinstein President | 412.1K | — | — | 1.09M | 212.2K | — | 1.71M | 63.48% | ↗ |
| 49 | 2019 | Chad Cohen Chief Financial Officer | 381.4K | — | — | 554.7K | 193.9K | — | 1.13M | 49.09% | ↗ |
| 50 | 2018 | Chad Robins Chairman and Chief Executive Officer | 422.8K | — | — | 2.51M | 266.5K | — | 3.19M | 78.42% | ↗ |
| 51 | 2018 | Harlan Robins, PhD Chief Scientific Officer | 348.9K | — | — | 1.67M | 158.5K | — | 2.18M | 76.70% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chad Robins | Co-Founder, Chief Executive Officer & Chairman | 1M | male |
| Harlan S. Robins | Co-Founder & Chief Scientific Officer | 834.5K | — |
| Julie Rubinstein | President & Chief Operating Officer | 820.5K | female |
| Sharon Benzeno | Chief Commercial Officer of Immune Medicine | 720.4K | — |
| Susan Bobulsky | Chief Commercial Officer of MRD | 666.2K | female |
| Kyle Piskel | Vice President, Chief Financial Officer & Principal Accounting Officer | 608.2K | male |
| Karina Calzadilla | Vice President of Investor Relations | — | female |
| Francis T. Lo | Chief People Officer | — | male |
| Mary Pat Lancelotta | Senior Vice President of MRD BioPharma | — | female |
| Christopher Carlson | Founder | — | male |
| Clarice McCauley | Head of Legal, Corporate Secretary, VP & Chief Compliance Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2022-02-14 | 2022-03-08 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ADPT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
